|
"ou dl"的相关文件
显示项目 1-10 / 15 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)
|
Chen, TWW;Hsu, CL;Wu, YC;Ou, DL;Su, YY;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2021-05-12 |
Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma
|
Hsu, CL;Ou, DL;Bai, LY;Chen, CW;Lin, L;Huang, SF;Cheng, AL;Jeng, YM;Hsu, C |
| 國家衛生研究院 |
2019-01-18 |
TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
|
Lai, HH;Li, CW;Hong, CC;Sun, HY;Chiu, CF;Ou, DL;Chen, PS |
| 國家衛生研究院 |
2015-09 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou, DL;Shyue, SK;Lin, LI;Feng, ZR;Liou, JY;Fan, HH;Lee, BS;Hsu, C;Cheng, AL |
| 國家衛生研究院 |
2014-12-15 |
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis
|
Wu, PC;Lu, JW;Yang, JY;Lin, IH;Ou, DL;Lin, YH;Chou, KH;Huang, WF;Wang, WP;Huang, YL;Hsu, C;Lin, LI;Lin, YM;James Shen, CK;Tzeng, TY |
| 國家衛生研究院 |
2014-01-03 |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou, DL;Lee, BS;Lin, LI;Liou, JY;Liao, SC;Hsu, C;Cheng, AL |
| 國家衛生研究院 |
2013-06-20 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway
|
Ou, DL;Lee, BS;Chang, YC;Lin, LI;Liou, JY;Hsu, C;Cheng, AL |
| 國家衛生研究院 |
2009-09-15 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou, DL;Shen, YC;Liang, JD;Liou, JY;Yu, SL;Fan, HH;Wang, DS;Lu, YS;Hsu, C;Cheng, AL |
显示项目 1-10 / 15 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
